Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis
30 avr. 2020 09h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 30, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has...
Galectin Therapeutics Update on the Impact of COVID-19
02 avr. 2020 08h03 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 02, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the...
Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update
16 mars 2020 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 16, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...
Galectin Therapeutics Appoints Seasoned Biopharmaceutical Executive Pol F. Boudes, M.D. as Chief Medical Officer
20 févr. 2020 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a leader in the field of NASH therapeutics, today announced the appointment of Pol F. Boudes, M.D. to the...
Galectin Therapeutics’ President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020
04 févr. 2020 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H....
Galectin Therapeutics’ Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology
09 déc. 2019 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that a paper...
Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH Cirrhosis
05 déc. 2019 12h05 HE
|
Galectin Therapeutics Inc.
Interim analysis after 12-18 months of treatment to reaffirm phase 2 results, select optimal dosage and sizing and seamlessly roll into Phase 3 stage of NASH-RX Study Dr. Harold Shlevin, CEO,...
Galectin Therapeutics to Webcast Corporate Update on December 4, 2019, after Annual Meeting of Stockholders
26 nov. 2019 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Harold H....
Galectin Therapeutics to Present at Anti-Fibrotic Drug Development (AFDD) Summit
18 nov. 2019 16h10 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Eliezer Zomer,...
Galectin Therapeutics Reports Q3 2019 Financial Results
12 nov. 2019 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...